27.85
+2.39%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Synmosa Biopharma
Its shares trade on Taipei Exchange under the ticker 4114.TWO. It has been listed since 9 September 2002. In the fiscal year to 31 December 2025, it reported revenue of TWD 6.19bn and net income of TWD 821.8m. At that date it held total assets of TWD 13.99bn and shareholders' equity of TWD 8.76bn.
Synmosa Biopharma Corp. engages in the manufacture and sale of ethical drug, over-the-counter drug, and healthcare products under Synmosa's trade mark. The company is headquartered in Taipei City, Taipei. The company went IPO on 2002-09-09. The firm's main products include respiratory drugs, cardiovascular and urinary drugs, gastrointestinal drugs, hormones, anti-tumor drugs, antibiotics and health products. The firm is also involved in the manufacture and sales of various kinds of cosmetics and animal medicines, as well as various kinds of chemical food additives and beverages. The firm distributes its products in domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 9 Sept 2002
- Website
- synmosa.com.tw ↗
Leadership
Pay as last reported
- Mr. Chih-Hui LinChairman of the Board, General Manager, since 1992
- Liyu HuangChief Financial Officer
- Ms. Jia-Xin ZhangSenior Vice President
- Ms. Yu-Yu LinVice President
- Ms. Ching-Hua TsaoHead of Accounting
- Ms. Chien-Yao YangCorporate Governance Officer
- Ms. Hui-Lan ChiuDirector
- Ms. Li-Wen HuangDirector
- Mr. You-Peng ZhangDirector
- Ms. Xiu-Mei LinIndependent Director
- Mr. Xiang-Lang LiuIndependent Director
- Mr. Sanqian TuIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Synmosa Biopharma Corp manufactures ethical drugs and over-the-counter products under its own trade mark.
- The firm produces respiratory drugs, cardiovascular drugs, and urinary drugs for diverse medical needs.
- Synmosa Biopharma Corp distributes its healthcare products to both domestic and overseas markets.
Weaknesses
- The company is headquartered in Taipei City, which may limit local operational flexibility.
- Synmosa Biopharma Corp went public on 9 September 2002, indicating a long listing history.
- The firm relies on the domestic market in Taiwan for a portion of its sales.
Opportunities
- Synmosa Biopharma Corp can expand its sales of anti-tumor drugs in emerging overseas markets.
- The firm may grow its segment of animal medicines and chemical food additives globally.
- Synmosa Biopharma Corp can increase revenue by selling more cardiovascular drugs internationally.
Threats
- Competition in the pharmaceuticals industry may reduce Synmosa Biopharma Corp's market share in Taiwan.
- Regulatory changes in overseas markets could hinder the distribution of Synmosa's ethical drugs.
- Economic shifts in the domestic market might decrease demand for Synmosa's healthcare products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.